BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026.
Rhea-AI Summary
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. CEO Kristen Fortney will take part in a fireside chat on April 16 from 3:00–3:30 PM EDT.
One-on-one meetings will include CFO Dov Goldstein and CSO BJ Sullivan. A live webcast is available by registration and replays will be archived for 30 days in the investor section of the company's website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BIOA
In the Apr 14 session, BIOA gained 2.35%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference dates
- April 13–16, 2026
- 25th Annual Needham Virtual Healthcare Conference
- Fireside chat time
- 3:00 PM–3:30 PM EDT
- CEO fireside chat on April 16
- Webcast archive period
- 30 days
- Replay availability on company investor website
- Price change
- -8.99%
- Move on day of conference announcement
- 52-week high
- $24
- Pre-news 52-week range
- 52-week low
- $2.88
- Pre-news 52-week range
- Shares outstanding
- 37,386,908 shares
- Common stock outstanding as of Dec 31, 2025 (S-3ASR prospectus)
- Stock options
- 7,914,058 options
- Outstanding options, weighted-average exercise price $7.74 (S-3ASR)
Historical Context
-
Nomination Committee proposed board slate and chair re-election for AGM.
-
Full-year 2025 results, positive BGE-102 Phase 1 data, and follow-on raise.
-
New long-term real-world lecanemab treatment data at AD/PD 2026.
-
Update on total shares and votes after stock option program issuance.
-
Announcement of BIOA presentation at Oppenheimer healthcare conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference taking place April 13–16, 2026.
Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, April 16 from 3:00 PM to 3:30 PM EDT. Kristen Fortney, Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.